Experts highlight key studies presented at the 2022 EHA annual meeting in this commentary from Clinical Care Options (CCO)
On-demand webcast from ProCE and Clinical Care Options (CCO), Rebecca Gonzalez, PharmD, BCOP, and Bhavesh Shah, RPh, BCOP, discuss the management of relapsed/refractory multiple myeloma
DETERMINATION trial: addition of ASCT to VRd followed by lenalidomide maintenance until disease progression, presented at ASCO 2022 and reported by Clinical Care Options (CCO)
Preliminary results suggest GC012F confers deep responses in heavily pretreated patients with relapsed/refractory multiple myeloma, presented at ASCO 2022 and reported by Clinical Care Options (CCO)
You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.